Pascal Bonnet
Orleans, 45067, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
An Experimentally Validated Structure-Based Virtual Screening Approach to Identify Nucleotide-Binding Protein Inhibitors as a New Source of Kinase Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 01, 2026
Frags2Drugs: A Novel In Silico Fragment-Based Approach to the Discovery of Kinase Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 15, 2026
Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships.
Journal: European journal of medicinal chemistry
Published: December 10, 2025
New fluoxetine analogues as anti-enterovirus agents targeting 2C protein.
Journal: European journal of medicinal chemistry
Published: November 14, 2025
Prozac 2.0 : from antidepressant to antiviral
Journal: Virologie (Montrouge, France)
Published: November 03, 2025
Spatio-temporal learning from molecular dynamics simulations for protein-ligand binding affinity prediction.
Journal: Bioinformatics (Oxford, England)
Published: February 19, 2025
Highlighting the Major Role of Cyclin C in Cyclin-Dependent Kinase 8 Activity through Molecular Dynamics Simulations.
Journal: International journal of molecular sciences
Published: March 26, 2024
Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization.
Journal: European journal of medicinal chemistry
Published: February 16, 2024
Virtual screening of natural products to enhance melanogenosis.
Journal: Molecular informatics
Published: December 06, 2023
The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells.
The Identification of New c-FLIP Inhibitors for Restoring Apoptosis in TRAIL-Resistant Cancer Cells.
Journal: Current issues in molecular biology
Published: December 05, 2023
Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis.
Journal: International journal of cosmetic science
Published: October 04, 2023
Last Updated: 09/26/2026